Hikma’s new compounding business, Hikma 503B, is set to address an increasing need in the US market for compounded sterile injectable medications while at the same time taking advantage of the company’s existing expertise in injectables to enter a market worth more than $2bn, according to CEO Siggi Olafsson.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?